35 day infected vs. control
Gene
Symbol
Control Avg.Ct ±SEM Infected Avg.Ct ±SEM Fold
change
p‐Value Gene
symbol
control Avg.Ct ±SEM Infected Avg.Ct ±SEM Fold
change
p‐value
Ccl1 13.26 ±0.25 11.66 ±0.25 3 0.016 Il27 12.87 ±0.30 9.73 ±0.27 8.8 0.012
Ccl17 9.41 ±0.15 7.97 ±0.34 2.7 0.041 Lta 10.67 ±0.19 9.22 ±0.05 2.7 0
Ccl2 6.72 ±0.14 5.44 ±0.17 2.4 0.007 Ltb 6.92 ±0.19 4.28 ±0.09 6.2 0
Ccl22 8.69 ±0.15 7.22 ±0.15 2.8 0.005 Tgfb2 1.26 ±0.14 3.70 ±1.24 0.2 0.021
Ccl24 11.25 ±0.08 13.93 ±0.94 0.2 0.012 Tnf 9.73 ±0.09 6.98 ±0.28 6.7 0.013
Ccl3 10.83 ±0.31 8.35 ±0.08 5.6 0 Tnfsf11 9.94 ±0.12 9.06 ±0.14 1.8 0.013
Ccl4 9.08 ±0.23 6.26 ±0.04 7 0 Xcl1 7.12 ±0.19 5.41 ±0.40 3.3 0.05
Ccl5 5.47 ±0.21 2.32 ±0.09 8.9 0 Adipoq 11.58 ±1.29 6.81 ±0.40 27.2 0.034
Cd40lg 13.94 ±0.93 8.64 ±0.16 39.4 0.001 Cd70 11.19 ±0.19 10.38 ±0.07 1.7 0.008
Csf2 11.51 ±0.29 8.78 ±0.16 6.6 0.002 Cntf 7.99 ±0.08 8.62 ±0.17 0.6 0.023
Cxcl10 9.18 ±0.19 5.08 ±0.27 17.1 0.005 Csf3 7.55 ±0.15 6.56 ±0.18 2 0.017
Cxcl13 8.83 ±0.27 4.51 ±0.36 20 0.017 Cxcl1 11.41 ±0.43 7.49 ±0.46 15.1 0.029
Cxcl16 5.00 ±0.23 3.14 ±0.13 3.6 0.002 Cxcl11 12.94 ±0.27 6.26 ±0.34 102.5 0.018
Cxcl9 8.06 ±0.22 2.41 ±0.26 50.3 0.006 Il10 11.18 ±0.41 8.77 ±0.15 5.3 0.003
Fasl 10.25 ±0.04 6.92 ±0.29 10.1 0.013 Il21 15.24 ±0.15 10.55 ±0.46 25.8 0.047
Ifna2 10.87 ±0.31 12.36 ±0.33 0.4 0.037 Il3 15.11 ±0.11 14.13 ±0.22 2 0.026
Ifng 10.76 ±0.16 7.33 ±0.09 10.8 0 Thpo 11.89 ±0.16 13.27 ±0.36 0.4 0.02
Il12b 10.31 ±0.23 8.46 ±0.12 3.6 0.002 Tnfsf10 5.82 ±0.18 3.80 ±0.19 4 0.004
Il16 7.75 ±0.11 6.75 ±0.20 2 0.02 Vegfa 4.23 ±0.13 4.83 ±0.09 0.7 0.023
Table 3: Effect of treatment on the expression of mRNAs in the uterus at 35 days post‐infection.